Remove 2022 Remove Clinical Trials Remove Epilepsy Remove Safety
article thumbnail

The Scott of Pot At It Again. Cann Group aiming for over-the-counter CBD approval in late 2022

Cannabis Law Report

Phase I clinical trial of the Satipharm CBD capsules in which results demonstrated the safety and high performance of the oral capsule technology, including the superior delivery profile of cannabidiol (CBD) compound to trial subjects. Cann Group (ASX: CAN) aiming for over-the-counter CBD approval in late 2022.

article thumbnail

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation

Cannabis Law Report

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Chapman continued.

article thumbnail

CBD Market Report

Project CBD

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: [link] Accessed October 17, 2022. February 2, 2022.

CBD 144
article thumbnail

Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

Cannabis Law Report

First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS About Altasciences.

article thumbnail

Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio

Cannabis Law Report

We recently announced that we anticipate commencing our initial human trial for Epoladerm™ in the second quarter of 2022. We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Virpax initially focused strictly on pain product candidates.